Abstract:Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the comorbidity of these brain disorders in aging individuals represents a significant challenge in basic research and clinical practice. The similarities and differences between stroke and AD in terms of pathogenesis and pathophysiology, however, have rarely been comparably reviewed. Here, we discuss the research background and recent progresses that are important and informative for the comorbidity of stroke and late-onset AD and related dementia (ADRD). Glutamatergic NMDA receptor (NMDAR) activity and NMDAR-mediated Ca2+ influx are essential for neuronal function and cell survival. An ischemic insult, however, can cause rapid increases in glutamate concentration and excessive activation of NMDARs, leading to swift Ca2+ overload in neuronal cells and acute excitotoxicity within hours and days. On the other hand, mild upregulation of NMDAR activity, commonly seen in AD animal models and patients, is not immediately cytotoxic. Sustained NMDAR hyperactivity and Ca2+ dysregulation lasting from months to years, nevertheless, can be pathogenic for slowly evolving events, i.e. degenerative excitotoxicity, in the development of AD/ADRD. Specifically, Ca2+ influx mediated by extrasynaptic NMDARs (eNMDARs) and a downstream pathway mediated by transient receptor potential cation channel subfamily M member (TRPM) are primarily responsible for excitotoxicity. On the other hand, the NMDAR subunit GluN3A plays a "gatekeeper" role in NMDAR activity and a neuroprotective role against both acute and chronic excitotoxicity. Thus, ischemic stroke and AD share an NMDAR- and Ca2+-mediated pathogenic mechanism that provides a common receptor target for preventive and possibly disease-modifying therapies. Memantine (MEM) preferentially blocks eNMDARs and was approved by the Federal Drug Administration (FDA) for symptomatic treatment of moderate-to-severe AD with variable efficacy. According to the pathogenic role of eNMDARs, it is conceivable that MEM and other eNMDAR antagonists should be administered much earlier, preferably during the presymptomatic phases of AD/ADRD. This anti-AD treatment could simultaneously serve as a preconditioning strategy against stroke that attacks ≥ 50% of AD patients. Future research on the regulation of NMDARs, enduring control of eNMDARs, Ca2+ homeostasis, and downstream events will provide a promising opportunity to understand and treat the comorbidity of AD/ADRD and stroke.

Glutamate receptors and white matter stroke

Impaired Meningeal Lymphatics and Glymphatic Pathway in Patients with White Matter Hyperintensity

Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke

Excitatory Synaptic Transmission in Ischemic Stroke: A New Outlet for Classical Neuroprotective Strategies

Excitotoxic Storms of Ischemic Stroke: A Non-neuronal Perspective

Acute and chronic excitotoxicity in ischemic stroke and late-onset Alzheimer's disease

[Advances in molecular mechanisms and therapeutic strategies of white matter injury after intracerebral hemorrhage]

White Matter Injury After Intracerebral Hemorrhage

Glial Cells: Role of the Immune Response in Ischemic Stroke

Role of glutamate transporter in the pathogenesis of cerebral ischemia in rats

Spatial and Temporal Mapping of Neuron-Microglia Interaction Modes in Acute Ischemic Stroke

Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease

Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke

Neuroprotection and neuroregeneration: roles for the white matter

Demyelination as a rational therapeutic target for ischemic or traumatic brain injury.

The Ties That Bind: Glial Transplantation in White Matter Ischemia and Vascular Dementia

Dynamics of Microglia Activation in the Ischemic Brain: Implications for Myelin Repair and Functional Recovery

The role of neuroglial cells communication in ischemic stroke

Role of Microglia in Stroke

Effect of glutamate transporter on neuronal damage induced by photochemical thrombotic brain ischemia:

Sustained blood glutamate scavenging enhances protection in ischemic stroke